These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20492322)

  • 1. Viral response guided therapy for hepatitis C in the approaching era of direct acting anti-viral agents.
    Berzsenyi MD; Roberts SK
    J Gastroenterol Hepatol; 2010 Apr; 25(4):655-6. PubMed ID: 20492322
    [No Abstract]   [Full Text] [Related]  

  • 2. [Predictive value of virological response on sustained virological response in hepatitis C patients].
    Zhou YQ; Wang XH; Fan Y; Zhu Y; Tan WT; Mao Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):944-6. PubMed ID: 20038340
    [No Abstract]   [Full Text] [Related]  

  • 3. Early identification of achieving a sustained virological response in chronic hepatitis C patients without a rapid virological response.
    Huang CF; Yang JF; Huang JF; Dai CY; Chiu CF; Hou NJ; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL; Yu ML
    J Gastroenterol Hepatol; 2010 Apr; 25(4):758-65. PubMed ID: 20492331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response-guided therapy: optimizing treatment now and in the future.
    Marcellin P; Rizzetto M
    Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
    [No Abstract]   [Full Text] [Related]  

  • 5. High sustained virological response rate to combination therapy in genotype 1 patients with histologically mild hepatitis C.
    Gheorghe L; Iacob S; Grigorescu M; Sporea I; Sirli R; Damian D; Gheorghe C; Iacob R
    J Gastrointestin Liver Dis; 2009 Mar; 18(1):51-6. PubMed ID: 19337634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].
    Song BC
    Korean J Gastroenterol; 2010 Jul; 56(1):59-61. PubMed ID: 20664319
    [No Abstract]   [Full Text] [Related]  

  • 7. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prediction of sustained viral response to combinational therapy with interferon and ribavirin in chronic hepatitis C by rapid viral response].
    Li MH; Chen LJ; Qiu GH; Lu Y; Xie Y; Xu DZ
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):497-500. PubMed ID: 19912682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
    Dusheiko G; Danta M
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):130-1. PubMed ID: 16265150
    [No Abstract]   [Full Text] [Related]  

  • 10. [Treatment of chronic hepatitis C].
    Fehér J; Lengyel G
    Orv Hetil; 2004 May; 145(20):1065-7. PubMed ID: 15202329
    [No Abstract]   [Full Text] [Related]  

  • 11. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retreatment with peginterferon and ribavirin in chronic hepatitis C.
    Jo YM; Lee SW; Han SY; Baek YH; Kim SY; Kim WJ; Ahn JH; Lee JY
    World J Gastroenterol; 2015 Feb; 21(6):1994-9. PubMed ID: 25684969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study).
    Juan Jd; de la Hoya PS; Marco A; Antón JJ; Faraco I; Yllobre C; Pozo E; Hoyos C
    Eur J Gastroenterol Hepatol; 2014 Oct; 26(10):1083-9. PubMed ID: 25076064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Occult hepatitis B virus infection in patients with chronic hepatitis C: An actor behind the scene or just a bystander?
    Chu CJ; Lee SD
    J Gastroenterol Hepatol; 2010 Feb; 25(2):221-3. PubMed ID: 20136983
    [No Abstract]   [Full Text] [Related]  

  • 15. Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
    Biermer M; Berg T
    Gastroenterology; 2009 Jul; 137(1):390-1. PubMed ID: 19486953
    [No Abstract]   [Full Text] [Related]  

  • 16. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapy of chronic Hepatitis C in 2008].
    Niederau C; Kaden T
    MMW Fortschr Med; 2008 Mar; 150(13):31-4. PubMed ID: 18522354
    [No Abstract]   [Full Text] [Related]  

  • 18. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
    Asahina Y; Izumi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
    [No Abstract]   [Full Text] [Related]  

  • 19. Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.
    Aghemo A; Rumi MG; De Nicola S; Colombo M
    Hepatology; 2010 Sep; 52(3):1170-1. PubMed ID: 20812363
    [No Abstract]   [Full Text] [Related]  

  • 20. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.